After the Omicron variant managed to hit the headlines, the CEOs and major shareholders of the Pfizer and Moderna saw a profit of a combined $10.31 billion, as per data compiled by the UK-based Global Justice Now.
Moderna shares rose 13.61% — $273.39 to $310.61 — between Nov. 24 and Dec. 1, whilst throughout the same time period Pfizer shared flew up 7.41% — $50.91 to $54.68, reports Common Dreams.
Stéphane Bancel, CEO of Moderna, witnessed his stock rise from $6.1 billion to $6.9 bil...
